

SENTINEL ARTICLES IN GYNECOLOGIC CANCER

Gestational Trophoblastic Neoplasia

Disclaimer: This list represents a collection of articles identified by members of SGO as important in the context of specific disease sites, it is not meant to serve as a specific tool of study for examinations and has not been approved by governing organizations in education.

1. Cole LA, Muller CY. Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. *Gynecol Oncol.* 2010;116(1):3–9.
<https://pubmed.ncbi.nlm.nih.gov/19822356/>
2. Cole LA, Laidler LL, Muller CY. USA hCG reference service, 10-year report. *Clin Biochem.* 2010;43(12):1013–1022. <https://pubmed.ncbi.nlm.nih.gov/20493830/>
3. Pezeshki M, Hancock BW, Silcocks P, et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. *Gynecol Oncol.* 2004;95(3):423–429.
<https://pubmed.ncbi.nlm.nih.gov/15581942/>
4. Curry SL, Schlaerth JB, Kohorn EI, et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group study). *Am J Obstet Gynecol.* 1989;160(4):805–809; discussion 809–811. <https://pubmed.ncbi.nlm.nih.gov/2540654/>
5. Homesley HD, Blessing JA, Rettenmaier M, et al. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. *Obstet Gynecol.* 1988;72(3 Pt. 1):413–418.
<https://pubmed.ncbi.nlm.nih.gov/2457192/>
6. Homesley HD, Blessing JA, Schlaerth J, Rettenmaier M, Major FJ. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1990;39(3):305–308.
<https://pubmed.ncbi.nlm.nih.gov/2175286/>
7. Lurain, J. R., Nejad, B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. *Gynecol Oncol* 2005, 97(2), 618-623. <https://pubmed.ncbi.nlm.nih.gov/15863169/>

8. Lurain, J. R., Singh, D. K., Schink, J. C. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. *J Reprod Med* 2006, 51(10), 773-776.
<https://pubmed.ncbi.nlm.nih.gov/17086805/>
9. Schmid, P., Nagai, Y., Agarwal, R., Hancock, B., Savage, P. M., Sebire, N. J., Seckl, M. J. (2009). Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. *Lancet* 2009, 374(9683), 48-55. <https://pubmed.ncbi.nlm.nih.gov/19552948/>
10. Lurain, J. R., Singh, D. K., Schink, J. C. (2010). Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7. *J Reprod Med* 2010, 55(5-6), 199-207. <https://pubmed.ncbi.nlm.nih.gov/20626175/>
11. Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. *J Clin Oncol.* 2011 1;29(7):825–831. <https://pubmed.ncbi.nlm.nih.gov/21263100/>
12. Yang, J., Zong, L., Wang, J., Wan, X., Feng, F., & Xiang, Y. Epithelioid Trophoblastic Tumors: Treatments, Outcomes, and Potential Therapeutic Targets. *J Cancer* 2019, 10(1), 11-19.
<https://pubmed.ncbi.nlm.nih.gov/30662520/>
13. Ghorani, E., Kaur, B., Fisher, R. A., Short, D., Joneborg, U., Carlson, J. W., ... Seckl, M. J. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. *Lancet* 2017, 390(10110), 2343-2345. <https://pubmed.ncbi.nlm.nih.gov/29185430/>
14. Campbell, G., Thomas, T. H., Hand, L., Lee, Y. J., Taylor, S. E., & Donovan, H. S. (2019). Caring for Survivors of Gynecologic Cancer: Assessment and Management of Long-term and Late Effects. *Seminars in oncology nursing*, 35(2), 192-201. <https://pubmed.ncbi.nlm.nih.gov/30867102/>
15. Schink JC, Filiaci V, Huang HQ, et al. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. *Gynecol Oncol.* 2020;158(2):354-360. doi:10.1016/j.ygyno.2020.05.013
PMID: 32460997. [GOG275] <https://pubmed.ncbi.nlm.nih.gov/32460997/>